Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease

NCT02620046 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02620046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02620046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
April 15, 2016
Completion date
June 12, 2024
Enrollment
746 (actual)
Sites
301

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative, crohn's disease